Loading…

Samyang Holdings signed a partnership agreement with Hangzhou Yxintent for the export of Lafullen dermal filler to China. Yxintent will conduct clinical trials and obtain approval, then exclusively sell the product, with Samyang supplying about KRW 100 billion worth over five years.
“Samyang Holdings signed a partnership agreement with Hangzhou Yxintent, a Chinese medical devices and aesthetics specialist company for the export of Lafullen.”prnewswire.com
Summarized from public sources; check the original articles before acting on it.